Core Insights - Procter & Gamble Company (PG) reported second-quarter fiscal 2026 results with earnings per share (EPS) exceeding estimates and year-over-year sales growth driven by improved pricing and a favorable mix [1][2] Financial Performance - The company achieved net sales of $22.21 billion, reflecting a 1% increase year over year, although it fell short of the Zacks Consensus Estimate of $22.29 billion [2] - Organic sales remained flat year over year, with a 1% increase from pricing offset by a 1% drop in volumes [2][4] - Core EPS was reported at $1.88, flat compared to the previous year but slightly above the Zacks Consensus Estimate [1] Segment Performance - Sales growth was led by a 5% increase in both Beauty and Health Care segments, a 1% increase in Fabric & Home Care, and a 2% increase in Grooming, while Baby, Feminine & Family Care saw a 3% decline [4] - Organic sales rose 4% for Beauty, 3% for Health Care, and remained flat for Grooming and Fabric & Home Care, with a 4% decline for Baby, Feminine & Family Care [4] Margin Analysis - Core gross margin declined by 50 basis points year over year to 51.9%, while reported gross margin fell by 120 basis points [6] - Core operating margin decreased by 70 basis points to 25.5%, primarily due to adverse currency effects [7] Cash Flow and Shareholder Returns - The company ended the quarter with cash and cash equivalents of $10.8 billion and generated an operating cash flow of $5 billion [9] - Procter & Gamble returned $4.8 billion to shareholders, including $2.5 billion in dividends and $2.3 billion in share buybacks [10] Fiscal 2026 Guidance - The company reiterated its fiscal 2026 guidance, expecting organic sales growth and core EPS growth between flat to 4% [11] - Revised net EPS growth outlook is now between 1-6%, down from the previous 3-9% range, reflecting increased non-core restructuring charges [12] - Anticipated commodity costs are expected to be neutral, with foreign exchange providing a tailwind of approximately $200 million after tax [13]

Core Insights - Procter & Gamble (PG) reported revenue of $22.21 billion for the quarter ended December 2025, reflecting a year-over-year increase of 1.5% and an EPS of $1.88, unchanged from the previous year [1] - The revenue fell short of the Zacks Consensus Estimate of $22.29 billion by 0.36%, while the EPS exceeded the consensus estimate of $1.87 by 0.33% [1] Financial Performance Metrics - Organic Sales Growth in Beauty was 4%, surpassing the estimated 2.2% [4] - Organic Sales Growth in Baby, Feminine & Family Care declined by 4%, worse than the estimated -2.2% [4] - Organic Sales Growth in Health Care was 3%, exceeding the average estimate of 1% [4] - Net Sales in Beauty reached $4.04 billion, above the estimated $3.99 billion, marking a year-over-year increase of 5% [4] - Net Sales in Grooming were $1.79 billion, slightly below the estimated $1.8 billion, with a year-over-year increase of 2.4% [4] - Net Sales in Corporate were $160 million, below the estimated $166.23 million, with a year-over-year increase of 0.6% [4] - Net Sales in Fabric & Home Care were $7.69 billion, slightly above the estimated $7.67 billion, with a year-over-year increase of 1.5% [4] - Net Sales in Baby, Feminine & Family Care were $5.12 billion, below the estimated $5.28 billion, reflecting a year-over-year decline of 3.3% [4] - Net Sales in Health Care were $3.41 billion, exceeding the estimated $3.31 billion, with a year-over-year increase of 4.8% [4] Earnings Performance - Earnings before income taxes in Beauty were $992 million, below the average estimate of $1.07 billion [4] - Earnings before income taxes in Grooming were $531 million, below the average estimate of $577.96 million [4] - Earnings before income taxes in Health Care were $1.01 billion, slightly above the estimated $995.8 million [4] Stock Performance - P&G shares returned +1.1% over the past month, outperforming the Zacks S&P 500 composite's +0.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

EARNINGS RELEASE Q2 FY 2026 Results January 22, 2026 BUSINESS RESULTS Q2 FY 2026 Q2 FY 2026 RESULTS Second quarter results heavily impacted by base period dynamics and underlying market trends. Organic sales were in-line with prior year. Pricing +1% offset by volume -1%. 7 of 10 product categories grew or held organic sales for the quarter. Global aggregate value share is down 20 basis points, with 25 of our top 50 category/country combinations holding or growing share for the quarter. Core earnings per sha ...

Core Insights - Procter & Gamble Company (PG) reported strong first-quarter fiscal 2026 results, with sales and earnings per share (EPS) exceeding estimates and showing year-over-year improvement [1][2] - The company's core EPS increased by 3% to $1.99, surpassing the Zacks Consensus Estimate of $1.90 [1][7] - Net sales reached $22.4 billion, reflecting a 3% year-over-year growth and exceeding the Zacks Consensus Estimate of $22.2 billion [2][7] Sales Performance - Organic sales rose by 2% year over year, driven by a 1% increase from pricing and a favorable product mix, while organic volume had a neutral impact [2][4] - Sales growth was led by a 6% increase in the Beauty segment, 5% in Grooming, 2% in Health Care, and 1% each in Baby, Feminine & Family Care and Fabric & Home Care [4][7] Margin Analysis - The core gross margin declined by 50 basis points to 51.5%, while the reported gross margin fell by 70 basis points [7][8] - Core selling, general and administrative expenses (SG&A) as a percentage of sales decreased by 40 basis points to 24.9% [9] - The core operating margin remained flat at 26.7%, with a currency-neutral increase of 40 basis points to 27.1% [10] Financial Position - Procter & Gamble ended the quarter with cash and cash equivalents of $11.2 billion and long-term debt of $24.3 billion [12] - The company generated an operating cash flow of $5.4 billion and an adjusted free cash flow of $4.9 billion, achieving a productivity rate of 102% [12][13] Shareholder Returns - In the first quarter, Procter & Gamble returned $3.8 billion to shareholders, including $2.55 billion in dividends and $1.25 billion in share buybacks [13] Fiscal 2026 Guidance - The company anticipates all-in sales growth of 1-5% for fiscal 2026, with organic sales expected to be flat to up 4% [14][15] - Core EPS is projected to grow by 3-9% compared to fiscal 2025, with a core EPS range of $6.83-$7.09 [15] - Procter & Gamble expects capital expenditure to be 4-5% of net sales and plans to pay out $10 billion in dividends and repurchase $5 billion in shares during fiscal 2026 [17]

Q1 FY 2026 Performance - Organic sales grew by 2% driven by pricing and mix[13] - Organic volume growth was flat at 0%[15] - Core earnings per share (EPS) increased by 3% to $1.99[14] - Currency-neutral core EPS also grew by 3%[14] - Adjusted free cash flow productivity was 102%[15] Segment Results - Beauty segment organic sales increased by 6% with volume up 4%[34] - Grooming segment organic sales grew by 3% with volume up 1%[37] - Health Care segment organic sales increased by 1% with volume down 2%[40] - Fabric & Home Care segment organic sales was flat at 0% with volume down 2%[43] - Baby, Feminine and Family Care segment organic sales and volume were flat at 0%[46] FY 2026 Guidance - Organic sales growth is projected to be between 0% and +4%[51] - Net sales growth is expected to be between +1% and +5%, including a 1% positive impact from foreign exchange and acquisitions/divestitures[51] - Core EPS growth is guided to be between +0% and +4%[53] - All-in EPS growth is projected to be between +3% and +9%[54] - The company anticipates ~$10 billion in dividends and ~$5 billion in direct share repurchases[57]

Group 1 - The Procter & Gamble Company (NYSE:PG) is recognized as one of the 11 Most Profitable Blue Chip Stocks to consider for investment [1] - Wells Fargo has revised its price target for Procter & Gamble from $173 to $170, reflecting a 1.73% decrease, while maintaining an Overweight rating [2] - Analysts show consistent confidence in Procter & Gamble's long-term growth, with BNP Paribas reiterating an Outperform rating at $177 and UBS lowering its target to $180 [2] Group 2 - Procter & Gamble has a diverse portfolio across various categories, generating approximately $85 billion in annual sales, with over 20 brands each exceeding $1 billion in international sales [3] - The company's stock stability is attributed to a balanced mix of high-growth and mature product areas, alongside ongoing global demand for consumer necessities [3][4] - Procter & Gamble offers branded consumer packaged goods in sectors such as Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care [4]

Core Insights - Procter & Gamble (PG) reported revenue of $20.89 billion for the quarter ended June 2025, marking a year-over-year increase of 1.7% and exceeding the Zacks Consensus Estimate by 0.39% [1] - The earnings per share (EPS) for the same period was $1.48, up from $1.40 a year ago, representing a surprise of 3.5% over the consensus estimate of $1.43 [1] Financial Performance Metrics - Organic Sales Growth for Beauty was 1%, below the average estimate of 1.7% [4] - Organic Sales Growth for Grooming was 1%, compared to the estimated 2.8% [4] - Total Organic Sales Growth for P&G was 2%, exceeding the average estimate of 1.4% [4] - Organic Sales Growth for Baby, Feminine & Family Care was 1%, above the estimate of 0.6% [4] - Organic Sales Growth for Fabric & Home Care was 1%, slightly below the estimate of 1.4% [4] - Organic Sales Growth for Health Care was 2%, below the average estimate of 3.1% [4] Net Sales Performance - Net sales for Beauty were $3.73 billion, slightly below the estimate of $3.76 billion, with a year-over-year change of +0.2% [4] - Net sales for Grooming were $1.68 billion, matching the average estimate, with a year-over-year increase of +1.6% [4] - Net sales for Corporate were $274 million, significantly above the estimate of $186.14 million, representing a +35.6% change year-over-year [4] - Net sales for Fabric & Home Care were $7.39 billion, slightly above the estimate of $7.36 billion, with a year-over-year change of +1.7% [4] - Net sales for Baby, Feminine & Family Care were $5.09 billion, exceeding the estimate of $5.02 billion, with a year-over-year change of +1.7% [4] - Net sales for Health Care were $2.72 billion, slightly below the estimate of $2.74 billion, with a year-over-year change of +1.8% [4] Stock Performance - P&G shares have returned -1.4% over the past month, while the Zacks S&P 500 composite has increased by +3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - FY2025 - Organic sales grew by 2% driven by volume and pricing[7] - Core earnings per share (EPS) increased by 4% to $6.83 compared to the prior year[8] - Currency neutral core EPS also increased by 4%[8] - Adjusted free cash flow productivity was 87%[9] Financial Performance - Q4 FY2025 - Organic sales grew by 2%[26] - Core EPS grew by 6%[26] - Currency neutral core EPS grew by 5%[26] - Adjusted free cash flow productivity was 110%[26] Shareholder Returns - The company returned $9.9 billion to shareholders via dividends and share repurchases in FY2025[23] - Total cash returned to owners over the past 10 years amounts to $151 billion[23] - Share repurchase amounted to $6.5 billion in FY2025[23] FY2026 Guidance - The company projects organic sales growth of +0% to +4%[55] - Net sales growth is projected to be +1% to +5%, including a 1% positive impact from foreign exchange and acquisitions/divestitures[55] - Core EPS growth is guided at +0% to +4%[57] - The company anticipates paying approximately $10 billion in dividends and repurchasing approximately $5 billion in shares[60]

Company Overview - Ontex Group NV is a leading international developer and producer of baby, feminine, and adult care products, serving both retailers and the healthcare sector [3] - The company distributes its innovative products in around 100 countries and employs approximately 7,000 people across 14 countries, with its headquarters located in Aalst, Belgium [3] - Ontex is listed on Euronext Brussel and is a constituent of the Bel Mid index [3] Financial Update - Ontex has announced an unconditional notice of redemption for its 3.500% Senior Notes due 2026, notifying holders that it will redeem all remaining outstanding Notes, along with accrued and unpaid interest, on July 15, 2025 [1] - Following a cash tender offer launched in March and concluded in April 2026, Ontex accepted €283,095,000 out of the originally issued €580,000,000, leaving a remaining outstanding amount of €296,905,000 [1]

Core Viewpoint - The recent sell-off in Procter & Gamble (P&G) stock presents a buying opportunity for investors seeking reliable passive income, despite the company's mediocre growth in recent years [2][10]. Group 1: Competitive Advantages - P&G possesses a strong portfolio of well-known brands across various categories, leading to high margins and sustained growth, with international sales exceeding domestic sales [4]. - The company effectively leverages its global supply chain and marketing, benefiting from diversification and avoiding over-reliance on a few brands [5]. - P&G focuses on expanding its existing brand lineup rather than pursuing large acquisitions, with its last major acquisition being Gillette for $57 billion two decades ago [6]. Group 2: Financial Performance and Dividends - P&G has consistently increased its dividend for 69 consecutive years, supported by steady growth in margins and free cash flow (FCF) per share, despite a current yield of 2.6% [10]. - The company generates significantly more FCF than needed for dividends, allowing for consistent stock buybacks, which have reduced the share count by 5.5% over the last five years and 13.6% over the last decade [12]. - P&G's earnings growth is driven by sales volume growth, price increases, operating margin expansion, and stock buybacks [12]. Group 3: Valuation and Investment Suitability - P&G commands a premium valuation due to its industry leadership and steady earnings, with a price-to-earnings (P/E) ratio of 26.3, which may appear high but is justified upon closer examination [13]. - The company's P/E and price-to-FCF ratios are around five-year median levels, suggesting potential for the stock to appear undervalued if earnings continue to rise [15]. - P&G is considered a foundational holding for risk-averse investors, particularly during economic downturns and geopolitical uncertainty, despite the presence of cheaper stocks with higher yields [16][17].